Rhythm Pharmaceuticals annual free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Rhythm Pharmaceuticals Free Cash Flow (FCF) History (RYTM)
Rhythm Pharmaceuticals reported −$116.6M in free cash flow for fiscal 2025, a decrease of $2.7M from the previous fiscal year, with a free cash flow margin of −61.46%.
View full Rhythm Pharmaceuticals company overviewRhythm Pharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$116.6M | −$2.7M | — | −61.46% |
| 2024 | 2024-12-31 | −$113.9M | $22.3M | — | −87.51% |
| 2023 | 2023-12-31 | −$136.2M | $37.5M | — | −175.91% |
| 2022 | 2022-12-31 | −$173.7M | −$27.3M | — | −734.87% |
| 2021 | 2021-12-31 | −$146.4M | −$24.2M | — | −4642.90% |
| 2020 | 2020-12-31 | −$122.2M | $3.9M | — | — |
| 2019 | 2019-12-31 | −$126.1M | −$63.4M | — | — |
| 2018 | 2018-12-31 | −$62.8M | −$33.2M | — | — |
| 2017 | 2017-12-31 | −$29.6M | −$5.3M | — | — |
| 2016 | 2016-12-31 | −$24.3M | −$17.3M | — | — |
| 2015 | 2015-12-31 | −$7.0M | — | — | — |
Rhythm Pharmaceuticals quarterly free cash flow
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2023 | 2023-12-31 | −$29.4M | $4.6M | — | −121.25% |
| Q3 2023 | 2023-09-30 | −$29.3M | $17.8M | — | −129.99% |
| Q2 2023 | 2023-06-30 | −$41.1M | −$2.2M | — | −213.78% |
| Q1 2023 | 2023-03-31 | −$36.5M | $17.3M | — | −318.07% |
| Q4 2022 | 2022-12-31 | −$34.0M | $6.5M | — | −386.81% |
| Q3 2022 | 2022-09-30 | −$47.1M | −$6.8M | — | −1099.02% |
| Q2 2022 | 2022-06-30 | −$38.9M | −$6.8M | — | −428.73% |
| Q1 2022 | 2022-03-31 | −$53.8M | −$20.2M | — | −3588.72% |
| Q4 2021 | 2021-12-31 | −$40.5M | −$8.3M | — | −2231.15% |
| Q3 2021 | 2021-09-30 | −$40.3M | −$6.4M | — | −3916.93% |
| Q2 2021 | 2021-06-30 | −$32.1M | −$4.2M | — | −11710.95% |
| Q1 2021 | 2021-03-31 | −$33.5M | −$1.4M | — | −95837.14% |
| Q4 2019 | 2019-12-31 | −$32.2M | −$15.0M | — | — |
| Q3 2019 | 2019-09-30 | −$33.9M | — | — | — |
| Q2 2019 | 2019-06-30 | −$27.9M | — | — | — |
| Q1 2019 | 2019-03-31 | −$32.2M | — | — | — |
| Q3 2018 | 2018-09-30 | −$17.3M | — | — | — |
Rhythm Pharmaceuticals free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$122.2M to −$116.6M, a net increase of $5.6M. Rhythm Pharmaceuticals's latest reported quarter, Q4 2023, generated −$29.4M in free cash flow, an increase of $4.6M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Rhythm Pharmaceuticals filings at SEC.gov ↗